Caribou Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Caribou Biosciences
CRBU Stock  USD 0.95  0.07  6.86%   
Caribou Biosciences financial statements provide useful quarterly and yearly information to potential Caribou Biosciences investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Caribou Biosciences financial statements helps investors assess Caribou Biosciences' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Caribou Biosciences' valuation are summarized below:
Gross Profit
-119.6 M
Market Capitalization
94.9 M
Enterprise Value Revenue
112.7254
Revenue
10 M
Earnings Share
(1.65)
There are currently one hundred twenty fundamental signals for Caribou Biosciences that can be evaluated and compared over time across rivals. All traders should validate Caribou Biosciences' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 136.4 M in 2025. Enterprise Value is likely to drop to about 146.1 M in 2025

Caribou Biosciences Total Revenue

15.78 Million

Check Caribou Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Caribou Biosciences' main balance sheet or income statement drivers, such as Net Interest Income of 119.7 K, Interest Income of 126.5 K or Depreciation And Amortization of 2.4 M, as well as many indicators such as Price To Sales Ratio of 13.65, Dividend Yield of 0.0 or PTB Ratio of 0.54. Caribou financial statements analysis is a perfect complement when working with Caribou Biosciences Valuation or Volatility modules.
  
Check out the analysis of Caribou Biosciences Correlation against competitors.
For more information on how to buy Caribou Stock please use our How to Invest in Caribou Biosciences guide.

Caribou Biosciences Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets304.3 M313.3 M157.6 M
Slightly volatile
Short and Long Term Debt Total15.3 M26.5 M6.5 M
Slightly volatile
Other Current Liabilities16.2 M23.6 M10.1 M
Slightly volatile
Total Current Liabilities24.8 M30.7 M15.7 M
Slightly volatile
Other Liabilities15 M20.7 M8.4 M
Slightly volatile
Property Plant And Equipment Net23.4 M39.3 M11.9 M
Slightly volatile
Current Deferred Revenue4.7 M3.1 M2.3 M
Slightly volatile
Accounts Payable2.1 M2.5 M2.6 M
Very volatile
Cash15.5 M16.3 M50.5 M
Pretty Stable
Non Current Assets Total67.6 M93.9 M30 M
Slightly volatile
Non Currrent Assets Other47.6 M45.4 M6.5 M
Slightly volatile
Other Assets1 M1.8 M836.5 K
Slightly volatile
Cash And Short Term Investments244.6 M209.5 M126.5 M
Slightly volatile
Net Receivables3.7 M2.1 M4.2 M
Very volatile
Common Stock Total Equity3.9 K6.9 K2.5 K
Slightly volatile
Common Stock Shares Outstanding74.3 M90.3 M63.7 M
Slightly volatile
Liabilities And Stockholders Equity304.3 M313.3 M157.6 M
Slightly volatile
Non Current Liabilities Total30.7 M29.7 M41.3 M
Slightly volatile
Other Current Assets6 M7.7 M2.6 M
Slightly volatile
Total Liabilities67 M60.4 M57.7 M
Slightly volatile
Property Plant And Equipment Gross54.8 M52.2 M13.9 M
Slightly volatile
Short and Long Term Debt758.5 K974 K652.5 K
Slightly volatile
Total Current Assets236.7 M219.4 M127.5 M
Slightly volatile
Capital Stock5.7 K9 K2.9 K
Slightly volatile
Non Current Liabilities Other745.8 K785 K1.1 M
Slightly volatile
Net Working Capital211.9 M188.7 M111.9 M
Slightly volatile
Short Term Debt2.4 M1.4 M1.6 M
Slightly volatile
Common Stock5.7 K9 K2.9 K
Slightly volatile
Property Plant Equipment6.4 M12.3 M5.7 M
Slightly volatile
Long Term Debt739.2 K831.6 K906.7 K
Slightly volatile
Capital Surpluse541.9 M574.5 M496.5 M
Slightly volatile
Deferred Long Term Liabilities19.7 M22.1 M24.1 M
Slightly volatile

Caribou Biosciences Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Net Interest Income119.7 K126 K707 K
Slightly volatile
Interest Income126.5 K133.2 K713.1 K
Slightly volatile
Depreciation And Amortization2.4 M4.1 M2.1 M
Slightly volatile
Interest Expense10.3 M9.8 M2.3 M
Slightly volatile
Selling General Administrative32.6 M46.5 M22.4 M
Slightly volatile
Total Revenue15.8 M10 M9.6 M
Slightly volatile
Other Operating Expenses112.3 M176.6 M67.9 M
Slightly volatile
Research Development79.7 M130.2 M45.4 M
Slightly volatile
Cost Of Revenue135.3 M128.9 M40.7 M
Slightly volatile
Total Operating Expenses112.3 M176.6 M67.9 M
Slightly volatile
Reconciled Depreciation2.1 M3.9 M1.3 M
Slightly volatile
Non Operating Income Net Other8.5 M8.1 M2.1 M
Slightly volatile
Selling And Marketing Expenses2.8 M3.2 M3.5 M
Slightly volatile

Caribou Biosciences Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation8.8 M16.7 M4.2 M
Slightly volatile
Begin Period Cash Flow83 M51.2 M59.2 M
Slightly volatile
Other Cashflows From Financing Activities1.5 M1.5 M7.5 M
Pretty Stable
Depreciation2.1 M3.9 M1.3 M
Slightly volatile
Capital Expenditures5.3 M4.9 M2.6 M
Slightly volatile
Total Cash From Financing Activities15.9 M16.7 M39.1 M
Slightly volatile
End Period Cash Flow15.5 M16.3 M50.5 M
Pretty Stable
Sale Purchase Of Stock345.9 M389.2 M424.3 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio13.6514.3692121
Slightly volatile
Days Sales Outstanding72.6276.4404205
Slightly volatile
Stock Based Compensation To Revenue1.761.67160.453
Slightly volatile
Capex To Depreciation1.961.24271.7031
Slightly volatile
EV To Sales14.6215.3892115
Slightly volatile
Payables Turnover33.9532.3313.2514
Slightly volatile
Sales General And Administrative To Revenue4.884.64852.8434
Pretty Stable
Research And Ddevelopement To Revenue13.6713.02315.309
Slightly volatile
Capex To Revenue0.260.48830.2221
Slightly volatile
Cash Per Share2.422.321.7513
Slightly volatile
Days Payables Outstanding8.699.14128
Pretty Stable
Income Quality1.020.92691.1806
Slightly volatile
Current Ratio6.827.15736.8048
Slightly volatile
Receivables Turnover2.94.7752.3557
Slightly volatile
Capex Per Share0.05540.0540.0377
Slightly volatile
Revenue Per Share0.170.11070.1441
Slightly volatile
Interest Debt Per Share0.150.29330.0867
Slightly volatile
Debt To Assets0.08880.08450.0275
Slightly volatile
Days Of Payables Outstanding8.699.14128
Pretty Stable
Ebt Per Ebit1.020.8950.9218
Slightly volatile
Quick Ratio7.217.15736.8338
Slightly volatile
Net Income Per E B T0.760.99990.8302
Slightly volatile
Cash Ratio0.50.53163.5163
Slightly volatile
Days Of Sales Outstanding72.6276.4404205
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.861.03531.0318
Very volatile
Fixed Asset Turnover0.240.25441.2874
Pretty Stable
Debt Ratio0.08880.08450.0275
Slightly volatile
Price Sales Ratio13.6514.3692121
Slightly volatile
Asset Turnover0.03030.03190.0924
Pretty Stable

Caribou Biosciences Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap136.4 M143.6 M797.5 M
Slightly volatile
Enterprise Value146.1 M153.8 M754.1 M
Slightly volatile

Caribou Fundamental Market Drivers

Cash And Short Term Investments209.5 M

Caribou Upcoming Events

14th of March 2024
Upcoming Quarterly Report
View
14th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
14th of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Caribou Biosciences Financial Statements

Caribou Biosciences shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Caribou Biosciences investors may analyze each financial statement separately, they are all interrelated. The changes in Caribou Biosciences' assets and liabilities, for example, are also reflected in the revenues and expenses on on Caribou Biosciences' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue3.1 M4.7 M
Total Revenue10 M15.8 M
Cost Of Revenue128.9 M135.3 M
Stock Based Compensation To Revenue 1.67  1.76 
Sales General And Administrative To Revenue 4.65  4.88 
Research And Ddevelopement To Revenue 13.02  13.67 
Capex To Revenue 0.49  0.26 
Revenue Per Share 0.11  0.17 
Ebit Per Revenue(16.67)(15.84)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Caribou Stock Analysis

When running Caribou Biosciences' price analysis, check to measure Caribou Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Caribou Biosciences is operating at the current time. Most of Caribou Biosciences' value examination focuses on studying past and present price action to predict the probability of Caribou Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Caribou Biosciences' price. Additionally, you may evaluate how the addition of Caribou Biosciences to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY